To the full analysis
Insmed stock: growth
INSMInsmed reported $606.42M in revenue for fiscal 2025, up 66.7% on the prior year, up 29.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
40.2%
per year from 2006 to 2025, per share 19%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 29.8% | no data | 40.2% |
| Revenue per share | 11.0% | no data | 19.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $991K | −$56.14M | −$47.22M |
| 2007 | $7.53M | −$19.96M | −$25.26M |
| 2008 | $11.7M | −$15.67M | −$11.99M |
| 2009 | $10.37M | $118.35M | −$11.01M |
| 2010 | $6.92M | −$6.43M | −$989K |
| 2011 | $4.42M | −$59.66M | −$31.18M |
| 2012 | $0 | −$41.37M | −$31.3M |
| 2013 | $11.5M | −$56.07M | −$47.49M |
| 2014 | $11.5M | −$79.16M | −$69.77M |
| 2015 | $0 | −$118.18M | −$104.15M |
| 2016 | $0 | −$176.27M | −$150.91M |
| 2017 | $0 | −$192.65M | −$162.62M |
| 2018 | $9.84M | −$324.28M | −$272.79M |
| 2019 | $136.47M | −$254.34M | −$292.92M |
| 2020 | $164.41M | −$294.09M | −$226.17M |
| 2021 | $188.46M | −$434.65M | −$370.59M |
| 2022 | $245.36M | −$481.53M | −$410.32M |
| 2023 | $305.21M | −$749.57M | −$549.54M |
| 2024 | $363.71M | −$913.77M | −$705.81M |
| 2025 | $606.42M | −$1.28B | −$967.58M |
Revenue by region
Where Insmed Incorporated generates its revenue.
- United States$453.0M75%
- Outside the US$153.5M25%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $452.95M | 74.7% |
| Outside the US | $153.47M | 25.3% |
| Total revenue | $606.42M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Feb 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.